FDA Approved: EVISTA — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

The FDA approved a supplemental application for EVISTA (raloxifene hydrochloride) from Eli Lilly and Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Osteoporosis

Drugs mentioned

• Evista (raloxifene)

Snippet

SUPPL AP for EVISTA (RALOXIFENE HYDROCHLORIDE)